🇺🇸 FDA
Pipeline program

SAR439774

EFC15467

Phase 3 small_molecule active

Quick answer

SAR439774 for Hemophilia is a Phase 3 program (small_molecule) at Genzyme Europe B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Genzyme Europe B.V.
Indication
Hemophilia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials